Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - progesterone, quantity: 200 mg - pessary, moulded - excipient ingredients: hard fat - oripro pessaries are indicated for:,1. assisted reproductive technology (art) treatment of infertile women with progesterone deficiency, requiring progesterone supplementation or replacement to support embryo implantation and maintain initial pregnancy.,2. prevention of preterm birth in singleton pregnancies at risk due to:,- shortened cervix (midtrimester sonographic cervix less than or equal to 25 mm). and/or,- where there is a history of spontaneous preterm birth.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - progesterone, quantity: 200 mg - pessary, moulded - excipient ingredients: hard fat - oripro pessaries are indicated for:,1. assisted reproductive technology (art) treatment of infertile women with progesterone deficiency, requiring progesterone supplementation or replacement to support embryo implantation and maintain initial pregnancy.,2. prevention of preterm birth in singleton pregnancies at risk due to:,- shortened cervix (midtrimester sonographic cervix less than or equal to 25 mm). and/or,- where there is a history of spontaneous preterm birth.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - progesterone, quantity: 100 mg - pessary, moulded - excipient ingredients: hard fat - oripro pessaries are indicated for:,1. assisted reproductive technology (art) treatment of infertile women with progesterone deficiency, requiring progesterone supplementation or replacement to support embryo implantation and maintain initial pregnancy.,2. prevention of preterm birth in singleton pregnancies at risk due to:,- shortened cervix (midtrimester sonographic cervix less than or equal to 25 mm). and/or,- where there is a history of spontaneous preterm birth.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - progesterone, quantity: 100 mg - pessary, moulded - excipient ingredients: hard fat - oripro pessaries are indicated for:,1. assisted reproductive technology (art) treatment of infertile women with progesterone deficiency, requiring progesterone supplementation or replacement to support embryo implantation and maintain initial pregnancy.,2. prevention of preterm birth in singleton pregnancies at risk due to:,- shortened cervix (midtrimester sonographic cervix less than or equal to 25 mm). and/or,- where there is a history of spontaneous preterm birth.

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate injectable suspension long-term [ see warnings and precautions ( 5.1) ]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [ see warnings and precautions ( 5.2) ]. - known or suspected malignancy of breast [ see warnings and precautions ( 5.3) ]. - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [ see warnings and precautions ( 5.5)

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - pessary, shell - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - luteal phase support ? luteal support of assisted reproductive technology (art) cycles,support during pregnancy ? prevention of preterm birth in women with singleton pregnancy who have a short cervix (midtrimester sonographic cervix less than or equal to 25 mm) and/or a history of spontaneous preterm birth. ? treatment of unexplained threatened miscarriage in women with bleeding in the current pregnancy and a history of at least three or more previous miscarriages. use in women with less than three miscarriages may be warranted in those with reduced chances of future pregnancy such as those undergoing ivf treatment with limited viable egg and/or embryo availability or advanced fertility age. however, the benefit of treatment in clinical trials was limited to women with three or more miscarriages. (see section 5 pharmacological properties; clinical trials; threatened unexplained miscarriage)

Canada - English - Health Canada

pharmascience inc - progesterone - capsule - 200mg - progesterone 200mg - progestins

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 10 mg - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to medroxyprogesterone acetate. - known liver impairment or disease. - known or suspected pregnancy.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 10 mg - medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. mpa tablets is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions. - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to mpa. - known liver impairment or disease. - known or suspected pregnancy.